OMED - OncoMed Pharmaceuticals, Inc.
| Previous Close | 1.0200 |
| Open | 1.0100 |
| Bid | 0.0000 x 400 |
| Ask | 0.0000 x 200 |
| Day's Range | 0.8701 - 1.0300 |
| 52 Week Range | 0.8700 - 5.0700 |
| Volume | 1,469,556 |
| Avg. Volume | 190,611 |
| Market Cap | 37.861M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | 6.36 |
| EPS (TTM) | 0.1540 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- Benzinga•3 days ago
The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...
- American City Business Journals•4 days ago
This Peninsula biotech foresaw deals worth $3 billion. Now it's lining up a $57 million merger
OncoMed's clinical trial failures prevented the Redwood City company from achieving the financial promise of deals with Celgene, Bayer and GlaxoSmithKline. Now a London company is reverse merging with it to get its NASDAQ listing and Peninsula facility.
- GlobeNewswire•5 days ago
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
Mereo BioPharma Group plc (MPH.L) (“Mereo”, the “Company” or the “Group”), the clinical stage UK based biopharmaceutical company focused on rare diseases, and OncoMed Pharmaceuticals, Inc. (OMED) (“OncoMed”), a NASDAQ listed oncology-focused clinical stage biopharmaceutical business, today announce the proposed combination of Mereo and OncoMed (the “Transaction”). The Transaction has been unanimously approved by the Board of Directors of each company.
- GlobeNewswire•25 days ago
Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•last month
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced initial results from the Phase 1a dose escalation portion of a Phase 1a/b trial of etigilimab, the company’s anti-TIGIT antibody. OncoMed’s anti-TIGIT checkpoint inhibitor candidate is an IgG1 monoclonal antibody which binds to the human TIGIT receptor on T-cells with a goal of improving the activation and effectiveness of T-cell and NK cell tumor-killing activity. The initial results from the Phase 1a dose escalation portion of the Phase 1a/b trial included data from 18 patients with a variety of late stage metastatic cancers including colorectal, endometrial, pancreatic, among others, who were treated with etigilimab at doses ranging from 0.3 to 20 mg/kg every other week.
- Simply Wall St.•last month
OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Delivered A Weaker ROE Than Its Industry
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
- Associated Press•last month
OncoMed: 3Q Earnings Snapshot
The Redwood City, California-based company said it had net income of 16 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•last month
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
-Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer; -Prepares for presentation.
- GlobeNewswire•2 months ago
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with 2 Prior Therapies and/or Prior.
- GlobeNewswire•2 months ago
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with 2 Prior Therapies and/or Prior.
- GlobeNewswire•2 months ago
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
REDWOOD CITY, Calif., Oct. 09, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel.
- GlobeNewswire•3 months ago
OncoMed Announces Publication of Phase 1a Data of Navicixizumab
REDWOOD CITY, Calif., Sept. 24, 2018-- OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that ...
- GlobeNewswire•3 months ago
OncoMed Provides Update on Navicixizumab Partnership
REDWOOD CITY, Calif., Sept. 20, 2018-- OncoMed Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that ...
- Simply Wall St.•3 months ago
Can OncoMed Pharmaceuticals Inc (NASDAQ:OMED) Improve Your Portfolio Returns?
Anyone researching OncoMed Pharmaceuticals Inc (NASDAQ:OMED) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...
- Zacks•4 months ago
OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates
OncoMed (OMED) delivered earnings and revenue surprises of 56.52% and -8.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
OncoMed: 2Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 10 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- Associated Press•7 months ago
OncoMed: 1Q Earnings Snapshot
The Redwood City, California-based company said it had a loss of 15 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- Zacks•7 months ago
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.
- Zacks•7 months ago
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.
